Drug Interaction Studies Reveal That Simotinib Upregulates Intestinal Absorption by Increasing the Paracellular Permeability of Intestinal Epithelial Cells

Herbst, 2004, Review of epidermal growth factor receptor biology, Int. J. Radiat. Oncol. Biol. Phys., 59, 21, 10.1016/j.ijrobp.2003.11.041 Levitzki, 2006, Tyrphostins and other tyrosine kinase inhibitors, Annu. Rev. Biochem., 75, 93, 10.1146/annurev.biochem.75.103004.142657 Haouala, 2011, Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Blood, 117, e75, 10.1182/blood-2010-07-294330 Togashi, 2011, Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer, Lung Cancer, 74, 98, 10.1016/j.lungcan.2011.01.022 Wardill, 2013, Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions, Curr. Opin. Support. Palliat. Care, 7, 155, 10.1097/SPC.0b013e32835f3e8c Groschwitz, 2009, Intestinal barrier function: molecular regulation and disease pathogenesis, J. Allergy Clin. Immunol., 124, 3, 10.1016/j.jaci.2009.05.038 Komarova, 2010, Regulation of endothelial permeability via paracellular and transcellular transport pathways, Annu. Rev. Physiol., 72, 463, 10.1146/annurev-physiol-021909-135833 Yamamoto, 1997, The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells, J. Cell Biol., 139, 785, 10.1083/jcb.139.3.785 Sheth, 2004, Epidermal growth factor prevents acetaldehyde-induced paracellular permeability in Caco-2 cell monolayer, Alcohol. Clin. Exp. Res., 28, 797, 10.1097/01.ALC.0000125358.92335.90 Singh, 2007, Juxtacrine activation of EGFR regulates claudin expression and increases trans-epithelial resistance, Am. J. Physiol. Cell Physiol., 293, C1660, 10.1152/ajpcell.00274.2007 Bretschneider, 1999, Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux, Pharm. Res., 16, 55, 10.1023/A:1018814627484 Ganapathy, 1998, Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2, Biochem. Biophys. Res. Commun., 246, 470, 10.1006/bbrc.1998.8628 Khan, 2003, Transport of parthenolide across human intestinal cells (Caco-2), Planta Med., 69, 1009, 10.1055/s-2003-45147 Krishna, 2001, Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2, Int. J. Pharm., 222, 77, 10.1016/S0378-5173(01)00698-6 Znalesniak, 2010, Modulation of cell-cell contacts during intestinal restitution in vitro and effects of epidermal growth factor (EGF), Cell. Physiol. Biochem., 25, 533, 10.1159/000303057 Herbst, 2005, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J. Clin. Oncol., 23, 5892, 10.1200/JCO.2005.02.840 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N. Engl. J. Med., 353, 123, 10.1056/NEJMoa050753 Gatzemeier, 2007, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial, J. Clin. Oncol., 25, 1545, 10.1200/JCO.2005.05.1474 Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1, J. Clin. Oncol., 22, 777, 10.1200/JCO.2004.08.001 Herbst, 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2, J. Clin. Oncol., 22, 785, 10.1200/JCO.2004.07.215 Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8 Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4 Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet Oncol., 13, 528, 10.1016/S1470-2045(12)70087-6 Hirsh, 2011, Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Curr. Oncol., 18, 126, 10.3747/co.v18i3.877 Kondoh, 2007, Tight junction modulators: promising candidates for drug delivery, Curr Med. Chem., 14, 2482, 10.2174/092986707782023640 Ooshio, 2010, Involvement of the interaction of afadin with ZO-1 in the formation of tight junctions in Madin-Darby canine kidney cells, J. Biol. Chem., 285, 5003, 10.1074/jbc.M109.043760 Yokoyama, 2001, α-Catenin-independent recruitment of ZO-1 to nectin-based cell-cell adhesion sites through afadin, Mol. Biol. Cell, 12, 1595, 10.1091/mbc.12.6.1595 Hare, 2007, The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib, Clin. Cancer Res., 13, 5170, 10.1158/1078-0432.CCR-07-0574 Lee, 2011, Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy, PLoS ONE, 6 Li, 2006, Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters, Drug Metab. Dispos., 34, 547, 10.1124/dmd.105.006791